Top

Published in:

01-02-2000

A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer

Authors: G. Schwartsmann, H. Schunemann, C.N.F. Gorini, A.F. Ferreira Filho, C. Garbino, G. Sabini, I. Muse, L DiLeone, D.R. Mans

Published in: Investigational New Drugs | Issue 1/2000

Title: A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer
Authors: G. Schwartsmann
H. Schunemann
C.N.F. Gorini
A.F. Ferreira Filho
C. Garbino
G. Sabini
I. Muse
L DiLeone
D.R. Mans
Publication date: 01-02-2000
Publisher: Kluwer Academic Publishers
Published in: Investigational New Drugs / Issue 1/2000
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1023/A:1006388031954

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 1/2000

Promising Approaches in Acute Leukemia

Advanced Non-Small Cell Lung Carcinoma: The Emerging Role of Docetaxel

Current Approaches and Future Strategies for Pancreatic Carcinoma

Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Instructions to Authors

Development of Target-Based Antineoplastic Agents

Keynote webinar | Spotlight on antibody–drug conjugates in cancer